A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF MAINTENANCE THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 09 May 2016 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
- 09 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.